Mochida Pharmaceutical Co., Ltd. (FRA:MFY)

Market Cap	699.90M -6.3%
Revenue (ttm)	628.03M +4.3%
Net Income	38.68M +48.1%
EPS	1.09 +48.3%
Shares Out	n/a
PE Ratio	18.10
Forward PE	n/a
Dividend	0.47 (2.50%)
Ex-Dividend Date	Sep 29, 2025

Volume	n/a
Average Volume	1
Open	19.00
Previous Close	19.30
Day's Range	19.00 - 19.00
52-Week Range	16.20 - 21.40
Beta	n/a
RSI	52.04
Earnings Date	Feb 6, 2026

About Mochida Pharmaceutical

Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. It offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology, including Lialda, Omvoh, and Cortiment for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Epadel for hyperlidemia and arteriosclerosis obliterans; Urece for gout and hyperuricemia; Treprost for the treatment of pulmonary arterial hypertension and p...

• Industry: Pharmaceutical Preparations
• Founded: 1913
• Employees: 1,508
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: MFY

Financial Performance

In fiscal year 2025, Mochida Pharmaceutical's revenue was 105.16 billion, an increase of 2.21% compared to the previous year's 102.89 billion. Earnings were 5.69 billion, an increase of 25.03%.

Financial numbers in JPY